Preparing for the incoming wave of biosimilars in oncology

Elena Wolff-Holz, Juan Garcia Burgos, Rosa Giuliani, Gustaf Befrits, Johan De Munter, Luisa Avedano, Murray Aitken, Rosa Gonzalez-Quevedo, Malvika Vyas, Elisabeth G.E. De Vries, Josep Tabernero

Research output: Contribution to journalReview articleResearchpeer-review

6 Citations (Scopus)


© Author (s) (or their employer(s)) 2018. With the imminent arrival of oncology biosimilars in the therapeutic paradigm, stakeholders including a clinician, specialist nurse, patient advocate, regulator and economist provide their perspective on optimising the uptake of these new agents in the treatment of cancer. A number of key messages emerge, based on the discussion that took place during a session of the European Society for Medical Oncology's Annual Congress, ESMO Madrid 2017. First, for successful integration of biosimilars into the global healthcare paradigm, informing and educating the full scope of stakeholders, including clinicians, nurses, pharmacists and patients, is primordial. Success is dependent on providing solid evidence and ensuring all voices are heard. Second, for oncology medicines, much can be learnt from the growing experience of approved biosimilars in other disease indications, with success stories for patients, their healthcare providers and healthcare budgets alike. Finally, effective sustainability of the impact on healthcare budgets and the redirection of these savings require education and transparency.
Original languageEnglish
Article numbere000420
JournalESMO Open
Issue number6
Publication statusPublished - 1 Sep 2018


  • biologicals
  • biosimilars
  • cancer medicines
  • monoclonal antibodies
  • oncology


Dive into the research topics of 'Preparing for the incoming wave of biosimilars in oncology'. Together they form a unique fingerprint.

Cite this